We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TOL:NYSEToll Brothers, Inc. Analysis

Data as of 2026-05-27 - not real-time

$137.85

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Toll Brothers is trading at $137.85, comfortably above its 20‑day SMA of $135.45 but slightly under the 50‑day SMA of $137.99, indicating short‑term momentum while still respecting a broader bearish bias (price below the 200‑day SMA of $140.02). The MACD histogram has turned positive (0.40) and the signal line is bullish, while the RSI sits at a neutral 52, suggesting the downside pressure may be easing. On the valuation side, the stock trades at a forward PE of 9.75 and a price‑to‑book of 1.55, well below the sector average, and analysts’ consensus target of $163.8 implies an upside of roughly 19%. Earnings recently beat expectations, with EPS rising to $13.16 and a modest dividend yield of 0.73% supported by a low payout ratio of 7.7%, underscoring dividend sustainability. However, revenue contracted 7.6% YoY, reflecting the cyclical nature of the luxury home market, and the 30‑day volatility remains elevated at 44% with a beta above 1.2. Recent news highlights a strong Q1 performance, an 8.3% share price rally, and an upgraded full‑year delivery guidance of 10,400‑10,700 homes, reinforcing confidence in the company’s execution.
Given the blend of attractive valuation, resilient margins (operating margin 15.1%, profit margin 11.7%), manageable leverage (debt‑to‑equity ~33%), and supportive analyst sentiment (Buy recommendation from 16 analysts), the stock appears positioned for a multi‑month upside, provided macro‑economic conditions for luxury housing remain stable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and 8.3% share price rally
  • Positive MACD crossover amid overall bearish trend
  • High 30‑day volatility and beta above market

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Raised FY2026 delivery guidance and full‑year outlook
  • Attractive valuation multiples (PE ~10, forward PE <10)
  • Low dividend payout ratio indicating sustainability

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong brand in the luxury residential segment
  • Solid balance sheet with manageable debt and cash reserves
  • Long‑term upside to analyst target price and demographic tailwinds

Key Metrics & Analysis

Financial Health

Revenue Growth-7.60%
Profit Margin11.66%
P/E Ratio10.5
ROE15.66%
ROA7.53%
Debt/Equity32.80
P/B Ratio1.6

Technical Analysis

TrendBearish
RSI52.0
Support$123.15
Resistance$148.77
MA 20$135.45
MA 50$137.99
MA 200$140.02
MACDBullish
VolumeIncreasing
Fear & Greed Index91.29

Valuation

Target Price$163.81
Upside/Downside18.83%
GradeUndervalued
TypeBlend
Dividend Yield0.73%

Risk Assessment

Beta1.28
Volatility43.77%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.